Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 12/20 | 0.64 |
| ▸ | SCN5A | Q14524 | 5/20 | 0.64 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | KMO | O15229 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | HRH2 | P25021 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6367996 | 0.89 | SCN9A (0.64) | SCN9ASCN5ADRD2SLC6A4RORC | |
| SCHEMBL899454 | 0.85 | SCN9A (0.64) | SCN9ASCN5ADRD2SLC6A4RORC | |
| SCHEMBL1260945 | 0.84 | SCN9A (0.65) | SCN9ASCN5ADRD2SLC6A4RORC | |
| SCHEMBL899425 | 0.82 | SCN9A (0.60) | SCN9ASCN5ADRD2SLC6A4RORC | |
| SCHEMBL27861253 | 0.82 | SCN9A (0.48) | SCN9ASCN5AKMOHRH2 | |
| SCHEMBL3078280 | 0.82 | SCN9A (0.48) | SCN9ASCN5AKMOHRH2 | |
| SCHEMBL27905588 | 0.77 | SCN9A (0.52) | SCN9ASCN5ADRD2SLC6A4APP | |
| SCHEMBL4822409 | 0.77 | SCN9A (0.44) | SCN9ASCN5AKMOHRH2 | |
| SCHEMBL27930381 | 0.77 | SCN9A (0.50) | SCN9ASCN5ADRD2SLC6A4RORC | |
| SCHEMBL9613192 | 0.76 | SCN9A (0.58) | SCN9ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140057928-A1 | SOLID STATE FORMS OF A POTENT HCV INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-27 | — | — | US | disclosed |
| US-8598183-B2 | Solid state forms of a potent HCV inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-12-03 | — | — | US | disclosed |
| US-20130288957-A1 | ORAL COMBINATION THERAPY FOR TREATING HCV INFECTION IN SPECIFIC PATIENT SUBGENOTYPE POPULATIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-31 | — | — | US | disclosed |
| US-20130261134-A1 | MESYLATE SALT FORMS OF A POTENT HCV INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-03 | — | — | US | disclosed |
| US-20130261050-A1 | ORAL COMBINATION THERAPY FOR TREATING HCV INFECTION IN SPECIFIC PATIENT SUB-POPULATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-03 | — | — | US | disclosed |
| WO-2013147750-A1 | ORAL COMBINATION THERAPY FOR TREATING HCV INFECTION IN SPECIFIC PATIENT SUB-POPULATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-03 | — | — | WO | disclosed |
| WO-2013147749-A1 | ORAL COMBINATION THERAPY FOR TREATING HCV INFECTION IN SPECIFIC PATIENT SUBGENOTYPE POPULATIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-03 | — | — | WO | disclosed |
| EP-2621921-A1 | SOLID STATE FORMS OF A POTENT HCV INHIBITOR | Boehringer Ingelheim International GmbH (DE) | 2013-08-07 | — | — | EP | disclosed |
| EP-2621495-A1 | COMBINATION THERAPY FOR TREATING HCV INFECTION | Boehringer Ingelheim International GmbH (DE) | 2013-08-07 | — | — | EP | disclosed |
| US-20120135949-A1 | COMBINATION THERAPY FOR TREATING HCV INFECTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-31 | — | — | US | disclosed |
| US-20120122887-A1 | SOLID STATE FORMS OF A POTENT HCV INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-17 | — | — | US | disclosed |
| WO-2012044520-A1 | SOLID STATE FORMS OF A POTENT HCV INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012041771-A1 | COMBINATION THERAPY FOR TREATING HCV INFECTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122887-A1 | SOLID STATE FORMS OF A POTENT HCV INHIBITOR | HAVCR2, SLC10A1, ZC3HAV1 | SCN9A 829/4885SCN5A 547/4885DRD2 4784/4885 |
| US-20130288957-A1 | ORAL COMBINATION THERAPY FOR TREATING HCV INFECTION IN SPECIFIC PATIENT SUBGENOTYPE POPULATIONS | IL36G, IL17A, IL6ST | SCN9A 400/4885SCN5A 1250/4885DRD2 2738/4885 |
| US-20130261050-A1 | ORAL COMBINATION THERAPY FOR TREATING HCV INFECTION IN SPECIFIC PATIENT SUB-POPULATION | SLC10A1, HAVCR2, GOT2 | SCN9A 3205/4885SCN5A 2348/4885DRD2 3092/4885 |
| US-20130261134-A1 | MESYLATE SALT FORMS OF A POTENT HCV INHIBITOR | SLC10A1, HAVCR2, ABL1 | SCN9A 651/4885SCN5A 351/4885DRD2 4697/4885 |
| US-20120135949-A1 | COMBINATION THERAPY FOR TREATING HCV INFECTION | HAVCR2, EIF2AK2, SLC10A1 | SCN9A 3837/4885SCN5A 3151/4885DRD2 4543/4885 |
| US-20140057928-A1 | SOLID STATE FORMS OF A POTENT HCV INHIBITOR | HAVCR2, SLC10A1, ZC3HAV1 | SCN9A 829/4885SCN5A 547/4885DRD2 4784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.